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Recent advances in computational biology suggest that any perturbation to the transcriptional
programme of the cell can be summarised by a proper ‘signature’: a set of genes combined with a pattern
of expression. Therefore, it should be possible to generate proxies of clinicopathological phenotypes and
drug effects through signatures acquired via DNA microarray technology.
Gene expression signatures have recently been assembled and compared through genome-wide
metrics, unveiling unexpected drug–disease and drug–drug ‘connections’ by matching corresponding
signatures. Consequently, novel applications for existing drugs have been predicted and
experimentally validated.
Here, we describe related methods, case studies and resources while discussing challenges and benefits
of exploiting existing repositories of microarray data that could serve as a search space for systematic
drug repositioning.Introduction
During past decades the main strategy of drug development has
been high-throughput screening of different molecules to identify
lead compounds showing activity against single therapeutic tar-
gets and pathways. However, the ratio of successfully identified
drugs to screened molecules has decreased dramatically over the
years [1]. Furthermore, targeting individual elements of patho-
genic pathways is not always a successful approach for tackling the
complexities of the disease state; even when a target pathway is
identified, a suitable drug might not be found. For example, in
Alzheimer’s disease the ‘amyloid hypothesis’ has driven the search
for drugs that stop aggregation of pathogenic beta-amyloid, which
generates potentially toxic oligomers and plaques, but so far these
efforts have not led to a successful disease-modifying treatment
[2]. In addition, the cost of bringing an effective drug to the market
is large and growing with a significant portion of investmentCorresponding author:. Saez-Rodriguez, J. (saezrodriguez@ebi.ac.uk)
5 These authors contributed equally to this work.
350 www.drugdiscoverytoday.com 1359-6446/06 2012 Eneeded in the research and development phase [3]. Many promis-
ing molecules never come into clinical use because they show
unfavourable pharmacokinetic properties or cause adverse reac-
tions in humans. As a consequence there is a pressing need to
identify successful treatments for many diseases in innovative
ways that could overcome these drawbacks.
Drug repositioning [4] is a potential alternative to new drug
discovery that promises to address some of these issues by identi-
fying new therapeutic applications for existing drugs. One of the
advantages of reconsidering established drugs is that they have
already been approved and, hence, they can potentially be re-
marketed in a faster and more cost-efficient way – by skipping
Phase I clinical trials [5]. Moreover, pharma company pipelines
already include many drug candidates that have passed Phase I
trials but were not successful in Phase II or III (i.e. being safe but
not sufficiently effective in treating the condition they were
originally designed for). This implies that the search basin for
repositionable drugs is vast and much larger than the set of
approved drugs [6].lsevier Ltd. http://dx.doi.org/10.1016/j.drudis.2012.07.014Open access under CC BY license.
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serendipity, such as the classic example of sildenafil which is
used to treat erectile dysfunction but was originally developed as
a cardiovascular drug [7]. However, systematic approaches have
recently been proposed. Most of these are based on the principle
that shared properties between compounds could hint at similar
efficacy or commonality in their mode of action (MoA). Success-
ful strategies based on this assumption have been devised and
published in different areas of computational drug discovery:
from chemoinformatics [8] and structural bioinformatics [9] to
text mining and meta-data analyses [10] and, recently, genome-
wide association studies [11]. Many of these strategies benefit
from recent advances in data integration and systems biology
[12] and among them a new trend has emerged over the past few
years that is based solely on the analysis of gene expression data
[13].
The traditional ‘central dogma’ of molecular biology is the
principle of genes encoding mRNA that is translated into proteins.
This defines a biological information flow that, moving through
levels of increasing complexity and emerging properties, links the
underlying genetic make-up of the cell to its clinicopathological
state [13]. In such a context, transcriptional profiling enables the
capture of a multidimensional view of this complexity at an
intermediate level, reflecting genomic and environmental effects.
So far in computational drug discovery, drug response and
disease phenotypes have been correlated with underlying patho-
logical processes through ‘back-tracking’ approaches that can infer
primary causes of transcriptional changes but require the integra-
tion of heterogeneous data sources and a priori known signalling
and regulatory models [14–16]. Transcriptional profiles have also
been used as a single data layer to dissect drug MoA through
reverse-engineering techniques [17]. By contrast, recent studies
suggest that purely data-driven approaches making use of gene
expression data alone are well suited to identifying new drug
repositioning opportunities. The leading idea is that comparing
the expression profile of a cell before and after exposure can
quantitatively assess the changes brought about by active com-
pounds on the transcriptional programme. The corresponding
signature of differential gene expression (SDE) can be considered
as the summary of the compound’s effect. Furthermore, a drug-
induced SDE can then be compared with a disease-associated SDE
similarly obtained through differential expression analysis of dis-
eased versus healthy conditions. If they are sufficiently negatively
correlated (i.e. the genes upregulated in the disease SDE are down-
regulated in the drug SDE and vice versa) then it is reasonable to
hypothesise that the effect of the drug on transcription is opposite
to the effect of the disease (Fig. 1a). As a consequence, the drug
might be able to revert the disease SDE and hence the disease
phenotype itself [18–20]. Alternatively, from a shared SDE it can be
hypothesised that two drugs could share a therapeutic application,
regardless of the similarity in their chemical structure and that
they impinge on different intracellular targets or pathways [21–24]
(Fig. 1b).
Despite the relative simplicity of these ideas, recent applications
have shown that they could serve as the basis for identifying drug
repositioning opportunities in different therapeutic areas to treat
heterogeneous diseases from cancer [25,26] to Alzheimer’s disease
[24] and Crohn’s disease [27].In the following sections we examine how gene transcription
profiles have been analysed in single case studies and we will
describe several publicly available resources; finally we discuss
challenges and future directions.
Matching gene expression signatures to ‘connect’
phenotypes
Pioneering studies have shown that collections of gene sets (i.e.
groups of genes sharing a common biological function, chromo-
somal location or regulation) can be used to interpret and extract
biological insights from genome-wide expression profiles, by using
parametric [28] or non-parametric statistical methods [29].
A genetic signature is defined by associating a gene set with a
specific pattern of expression [30]. Gene expression profiling has
been widely used as phenotype proxies [31], to build phenotype
taxonomies [30,32], for systematic functional discovery [33] and
for classification and/or cataloguing purposes [30,34]. Most impor-
tantly, gene expression signatures have been effective in recover-
ing ‘connections’ between genes, drugs and diseases involving (or
involved in) the same biological process, by combining a large
collection of gene expression data following drug treatment with a
pattern-matching method [35]. A seminal example of this is given
by the Connectivity Map (cMap) [18,35], which is the first large
public database of genome-wide gene expression profiles from five
different human cancer cell lines treated with more than 1000
bioactive small molecules.
The aim of the cMap project was to generate a ‘map’ that can be
searched for ‘connections’ between gene expression profiles asso-
ciated with disease states and those following treatment with a
large set of existing drugs. To query this map, the authors devised a
pattern-matching tool based on Gene Set Enrichment Analysis
(GSEA) [29] through which these connections can be inferred and
statistically assessed.
The effectiveness of this method for in silico drug discovery and
drug repositioning has been demonstrated already by its very first
applications [36,37], and it highlights the potential of gene tran-
scription profiling to serve as the common language to link
chemistry, biology and the clinic, by inferring genome-wide simi-
larities or differences [35]. Numerous studies have been published
using the cMap dataset and the cMap tool, with different aims (a
comprehensive list is provided on the cMap website). This under-
scores the power of gene expression profiles and gene signatures in
characterising biological states and acting as a surrogate pheno-
type, despite the difficulty in interpreting the meaning of pre-
dicted associations, let alone the precise part played by individual
genes in these signatures [31]. Subsequent achievements have
been to characterise the whole landscape of human gene expres-
sion [38], to establish large repositories of transcriptional data
[39,40] and to make publically available a large amount of gene
expression data that could be mined to compose drug and disease
signatures (Fig. 2). Moreover, the robustness of these signatures
has been shown across tissue types and experiments [41] and,
during the past two years, the use of transcriptional data for drug
repositioning has emerged as a useful and effective strategy
[13,42], bringing about a new dawn for the vast quantities of
DNA microarray data already in the public domain.
Although numerous approaches for in silico drug repositioning
based on gene expression data have been published [19,20,22,24,www.drugdiscoverytoday.com 351
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FIGURE 1
Signature reversion (a) and guilt-by-association (b) approaches in gene-expression-based drug repositioning. In (a) the aim is to identify a drug where the effect
on transcription is opposite to a disease signature. In (b) drugs eliciting similar gene expression signatures are sought and hypothesised to share a common mode
of action. Many publicly available repositories can be queried to generate drug and disease signatures that can be compared to each other and integrated with
newly generated experimental data (c).
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make use of the cMap SDEs as a reference database of drug responses
in combination with signature-matching strategies. The majority of
these methods can be subdivided into two main classes (features of
which are summarised in Fig. 1). Methods in the first class aim to
identify novel ‘drug–disease’ connection, whereas those in the
second class aim to infer ‘drug–drug’ connections. In both cases
gene expression profiles are used to summarise drug responses and
disease states; and comparison between the two are based on the
following simple but powerful assumptions:
(i) If an SDE summarising the response to a given approved drug
is sufficiently negatively correlated to the SDE characterising
a disease state, then that drug might be able to ‘revert’ the
disease signature, hence the drug might be able to treat the
disease phenotype. If already approved for other uses, the
drug could be repositioned to treat that disease (Fig. 1a).352 www.drugdiscoverytoday.com(ii) If two drugs elicit similar SDEs, even if acting on different
intracellular targets, they could share a common MoA. In this
case, the first drug could be repositioned to treat conditions
for which the second drug has already been approved, or vice
versa (Fig. 1b).
In the following section we will review case studies for methods
in both classes.
Reverting phenotype signatures to revert phenotypes
In this section we review methods based on the assumption that a
drug that can revert a disease SDE might revert the disease phe-
notype itself. Building on this idea, several successful studies
(methodologically similar to each other) identified new drugs
for hepatocellular carcinoma [26], and were able to show the
efficacy of vorinostat (currently used to treat cutaneous T-cell
lymphoma) in treating gastric cancer [43] and also to predict
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FIGURE 2
Rate of growth of ArrayExpress data in terms of experiments (i.e. user
submission). This trend is set to increase further in the future, as new high-
throughput sequencing-based transcriptomic applications result in the
generation of huge amounts of data.
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[20,25].
Owing to their robust experimental validation and the meth-
odological similarity with other cited works, here we concentrate
on two representative case studies. The first is presented in a
publication by Dudley et al. [27]. As a first step, the authors
assembled an SDE for inflammatory bowel disease (IBD), which
is a chronic inflammatory gastrointestinal disorder for which only
few safe and effective drugs exist, from public gene expression data
[40]. Then they mined the cMap dataset to identify drugs that had
SDEs that opposed those of IBD. They then developed an algo-
rithm to generate a ‘therapeutic score’ for each of the drugs in the
cMap, applying a significance threshold value to determine when a
drug SDE was opposite to the disease SDE. Among the top-ranked
therapeutic predictions, the authors found not only the corticos-
teroid prednisolone (for which the efficacy in treating IBD has
already been established and therefore defined as a positive con-
trol) but also, interestingly, a second candidate topiramate, an
anticonvulsant drug approved for epilepsy, never linked before to
IBD, which had a predicted therapeutic score higher than that of
prednisolone. The authors used a trinitrobenzenesulfonic (TNBS)
acid induced rodent model of IBD to validate their prediction in
vivo. They showed that topiramate treatment improved damage in
colon tissue which was one of the most severe symptoms of the
induced phenotype. They therefore suggested that, given its safety
profile, topiramate could indeed be repositioned to treat IBD in
humans.
In a similar study, Kunkel et al. [45] generated SDEs of skeletal
muscle atrophy, a condition currently lacking pharmacological
therapy, by chronic fasting in human patients and mouse models.
They used the resulting two SDEs to search the cMap database and
both their queries returned ursolic acid as the only compound with
an SDE opposite to that of the disease state. The authors went on toverify experimentally that ursolic acid reduced muscle atrophy
and stimulated muscle hypertrophy in mice. They identified the
MoA to be enhancement of skeletal muscle insulin/insulin-like
growth factor-1 (IGF-1) signalling and inhibition of atrophy-asso-
ciated skeletal muscle mRNA expression. Moreover, they observed
additional effects on the characteristics of muscle following treat-
ment with ursolic acid, including reductions in adiposity, fasting
blood glucose, plasma cholesterol and certain triglycerides. These
findings suggest a potential use of ursolic acid in muscle atrophy
and other metabolic myopathies. With respect to the study by
Dudley et al. [27], the methodological difference is that here the
authors used a partial SDE composed only of genes with significant
differential expression in skeletal muscle atrophy, rather than
using a genome-wide SDE. Moreover, the authors used the cMap
query tool for matching these partial SDEs to compounds rather
than designing their own therapeutic score.
In the remainder of this section we describe how the signature
reversion strategy has been used successfully to predict synergistic
drug combinations when matching drug SDEs with SDEs charac-
terising biological states other than diseases, thus highlighting the
generality of such a method.
Motivated by the aim of reducing drug resistance of a cancer in a
pharmacological way, Wei et al. successfully identified rapamycin
as a modulator of glucocorticoid resistance in acute lymphoblastic
leukaemia [46]. As in the previous cases, the first step was to
identify an SDE representing a biological state to be ‘reverted’
by a drug. However, rather than using an SDE derived from a
generic disease state, the authors derived a gene expression sig-
nature that differentiated acute lymphoblastic leukaemia samples
sensitive to glucocorticoids from glucocorticoid-resistant samples,
hence generating a drug resistance SDE rather than the SDE of a
disease. Furthermore, the authors searched the cMap dataset for
drugs with an SDE matching the signature they computed in an
opposite way, identifying several potential active compounds. The
top ranked drug in this list was rapamycin. Further analysis found
that rapamycin elicits a sensitising action to glucocorticoids by
acting on the antiapoptotic factor MCL1 (induced myeloid leu-
kaemia cell differentiation protein).
In a similar study, Hassane et al. identified drugs that enhanced
the antileukaemic effect of partenolide, a drug effective at redu-
cing the survival and leukemogenic activity of primary human
acute myeloid leukaemia stem cells [47]. However, partenolide
induces cellular protective responses that reduce its cytotoxicity.
As the starting point the authors selected a previously published
SDE of response to partenolide. With this signature they queried
the cMap database and they identified compounds acting along
the phosphatidylinositol-3-kinase and mammalian target of rapa-
mycin (mTOR) pathways among those eliciting an SDE similar to
that of partenolide. Finally, they verified that treating acute mye-
loid leukaemia cells with a combination of partenolide and phos-
phatidylinositol-3-kinase/mTOR inhibitors was more effective
than treating with partenolide alone at decreasing the viability
of cells and tumour burden in vitro and in murine xenotransplan-
tation models.
Taken together, these studies clearly show the potential of
‘signature reversion’ in identifying new uses for existing drugs
as well as to predict novel chemosensitising effect and synergistic
drug combinations.www.drugdiscoverytoday.com 353
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a shared MoA
In contrast to the examples in the previous section, here we review
approaches based on the assumption that if two drugs elicit similar
transcriptional responses then they could share a MoA and hence
could be applied to the same pathological condition.
Inferring drug target binding by comparing the molecular simi-
larity of sets of candidate drug compounds has been a traditional
approach in drug discovery. This is ligand-based drug design and
has been most often applied when structural information regard-
ing the target proteins and their binding sites are absent. Candi-
date drug compounds known to inhibit the same target protein
can be compared using their chemophoric (interaction) patterns.
However, only when the 3D geometries of their interaction pat-
terns match can a pharmacophore (the complementary set of
binding interactions) be inferred representing the possible shared
binding site of the target protein. Comparisons of interaction
geometries can be seen in the literature reporting QSAR and
comparative molecular field analysis (CoMFA) studies of two or
more drug compounds that share a common target or equivalent
binding sites in homologous proteins [48]. Conversely, a compar-
ison of binding sites known to be targeted by one set of inhibitors
and drugs can be used to infer equivalent binding sites in new
targets. Consequentially, the target of a new drug can, in principle,
be deduced by looking at the targets of the drugs most similar to it.
This ‘guilt-by-association’ principle has been successfully applied
to identify new targets for existing drugs [8], by defining the
corresponding set of ligands for a large number of known targets
and then computing chemical similarities between drugs and ligand
sets. In addition to structural similarity, the same principle has been
applied to exploit other kinds of drug similarity in MoA discovery
and repositioning in structural bioinformatics [9] where proteins
with similar binding sites are targeted by the same drug; text mining
[10], where two drugs sharing a semantic concept are assumed to
share a therapeutic application; recently, ‘modulatory profiling’
[23], measuring changes in efficacy of lethal compounds when used
in combination with a second cell-death-modulating agent (here
drugs with similar modulatory profiles could have the same MoA);
finally, as mentioned above, gene expression data, where two drugs
elicit a similar SDE and could have a common MoA even if they act
on different intracellular targets [22].
Based on the premise of shared genome-wide molecular activity,
Iorio et al. [22] systematically compared all the cMap drugs in a pair-
wise fashion, rather than searching for drugs eliciting an SDE similar
or opposite to an input signature. By doing this they identified a
large number of drug–drug ‘associations’ based on the extent of
similarity between the corresponding SDEs. By making use of a
novel similarity score, they constructed a network representation in
which each node is a drug and each edge (connection) indicates a
significant similarity between the SDEs of the connected nodes.
They divided the drug network into groups of densely intercon-
nected nodes termed ‘communities’, containing drugs eliciting
similar SDEs. Communities were strikingly populated by drugs with
similar known MoAs or sharing a therapeutic application.
The authors demonstrated the power of their method to identify
the MoA of novel drugs by analysing their neighbouring commu-
nities once they were integrated in the network. In a similar way,
they showed how the drug network could be used to infer new354 www.drugdiscoverytoday.comapplications for already existing drugs by searching subnetworks
surrounding a drug with a desired MoA for other compounds never
linked before to that MoA. By doing this, they were able to predict
and experimentally verify that fasudil, a safe Rho-kinase inhibitor
approved in Japan to reverse blood vessel obstructions after
ischemic stroke, can enhance cellular autophagy [21], a metabolic
process implicated in several neurodegenerative disorders.
A related method was proposed by Hu and Agarwal [24], who
inferred a drug–disease network in which two nodes were con-
nected by an edge if the corresponding SDEs were significantly
similar (in the case of drug–drug connections) or significantly
negatively correlated (in the case of drug–disease connections).
To achieve this, the authors integrated the SDE of the cMap drugs
with a large number of disease SDEs assembled by mining the Gene
Expression Omnibus (GEO) repository [40]. Connections repre-
senting anticorrelations were predictive of new indications for
existing drugs, such as the potential use of some antimalarial
drugs for Crohn’s disease, and the possible repositioning of several
existing drugs as therapeutic options for Huntington’s disease.
This approach can be seen as a precursor hybrid method, mixing
together the two types of approaches of disease signature reversion
and guilt-by-association. Moreover, the authors hypothesise that
drug side effects could be predicted by the analysis of similarity
between drug and disease SDEs.
In conclusion, the results presented show how large collections
of gene expression data following drug treatment could be
exploited through a guilt-by-association approach with the aim
of identifying drug repositioning opportunities.
Resources for computational expression-based drug
repositioning
Several resources support computational drug repositioning based
on transcriptional data and the functional characterisation of gene
sets and signatures. Some freely available tools and database are
listed in Table 1.
ArrayExpress [39], GEO [40] and the cMap [18,35] are large public
repositories of gene expression data from where disease and drug-
response signatures can be assembled. DAVID [49], MsigDB [29] and
GeneSigDB [50] are useful tools for functionally characterising large
gene lists by using pre-defined functional terms, or pre-defined gene
signatures representing different biological entities and processes
from public repositories. These signatures can also be used to
characterise with regard to function large sets of differentially
expressed genes from microarray studies through non-parametric
statistical methods that can also provide complementary informa-
tion, such as the GSEA tool [29] or Expression Analysis System
Explorer (EASE) and regulatory motif analysis [51,52].
The cMap query tool has two extensions: sscMap [53,54] and the
MoA by network analysis (MANTRA) tool [22]. sscMAP is a free-to-
download java implementation of the cMap algorithm bundled
with the reference dataset, enabling the integration of user-defined
data. MANTRA makes use of a post-processed version of the cMap
dataset, where compounds are catalogued into a drug similarity
network. In this network two drugs are connected if they elicit a
similar transcriptional response in human cell lines. With MANTRA
users can integrate a drug under investigation into the network and
deduct its MoA by analysing the surrounding subnetwork. More-
over, it is possible to identify drug repositioning opportunities by
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TABLE 1
Publicly available resources to derive, compare and functionally characterise gene expression signatures
Resource Short description Minable for partial
and genome-wide
signatures of drug
responses and
disease states
Tool for signature
matching and
classification of
microarray data
Functional
characterisation
of gene sets/
signatures
Oriented to
drug-discovery
and repositioning
Website
ArrayExpress Public repositories of gene expression data U http://www.ebi.ac.uk/arrayexpress/
Gene Expression
Omnibus – GEO
http://www.ncbi.nlm.nih.gov/geo/
Database for
Annotation,
Visualization
and Integrated
Discovery – DAVID
Functional annotation tools to associate
biological meaning to list of genes through
analysis of over-represented terms
U http://david.abcc.ncifcrf.gov/
Gene Expression
Atlas
Subset of ArrayExpress archive, servicing
queries for condition-specific gene expression
patterns
U U http://www.ebi.ac.uk/gxa/
Molecular Signature
Database – MsigDB
Collections of annotated gene signatures
from different sources
U U http://www.broadinstitute.org/
gsea/msigdb
Gene Signature
Database –
GeneSigDB
http://compbio.dfci.harvard.edu/
genesigdb/
Gene Set Enrichment
Analysis – GSEA
Tool able to determine if an a priori defined
gene signature shows statistically significant,
concordant differences between two
biological states
U U http://www.broadinstitute.org/gsea
ProfileChaser Tools to search the GEO repository for
experiments whose differential expression
looks similar or opposite to a gene expression
signature or a query experiment
U U http://profilechaser.stanford.edu/
MicroArray Rank
Query – MarQ
http://marq.dacya.ucm.es/
Connectivity
Map – cMap
Large collection of gene expression data
following drug treatment that can be queried
with an integrated pattern-matching tool,
based on GSEA, to find drugs eliciting a
response similar or opposite to a given gene
signature
U U U http://www.broadinstitute.org/cmap/
Statistically
significant
connections’
map – sscMap
Java implementation of the cMap tool
bundled with the corresponding dataset and
making it extendable with adding custom
collections of reference profiles
U U http://purl.oclc.org/NET/sscMap
Mode of Action
by NeTwoRk
Analysis –
MANTRA
Tool for the analysis of the mode of action of
novel drugs and the identification of drug
repositioning opportunities, based on
network theory and GSEA and making use of
a post-processed version of the cMap
database
U U U http://mantra.tigem.it
Drug versus Disease – DvD Computational pipeline for comparing
disease and drug-response gene expression
signatures from publicly available resources
U U U www.ebi.ac.uk/saezrodriguez/dvd
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MoA for ‘safe’ compounds never linked before to that MoA.
Several tools are freely available for mining gene expression data
repositories based on similarity with an input signature in a similar
manner to cMap. ProfileChaser [55] searches microarray repositories
based on genome-wide patterns of differential expression, and
MARQ [56] mines GEO for experiments that generate a differential
expression profile that is similar or anti-correlated to an input gene
expression signature. Finally, DvD is a recently developed tool
providing a pipeline for the comparison of drug and disease gene
expression profiles from public microarray repositories.
Challenges of signature-matching methods
A potential major problem affecting the methods described here is
the challenge of integrating independent microarray studies.
Microarrays do not measure gene expression in absolute units.
As a consequence, an improper handling of multiple gene expres-
sion profiles obtained in different experimental settings would
capture similarities in these settings rather than in the represented
biological states (a phenomenon known as the ‘batch effect’ [57]).
By contrast, cells in different pathological conditions or with
different genomic backgrounds respond very differently to the
same drug treatment. Consequently, classic microarray analysis
approaches might not produce optimal results, because they tend
to discriminate gene expression profiles on the basis of the experi-
mental settings in which they have been produced rather than on
the basis of the stimuli they are responding to (for example a drug
treatment).
In most of the methods we describe in this review, these
problems are partially addressed by making use of non-parametric
statistics [29], genome-wide ranked lists of genes [18] and ‘con-
sensual responses’ to drugs [22] rather than classic similarity
metrics applied to individual profiles of expression values or
fold-change-derived significance scores. However, a potential
drawback of these techniques is that they might dilute cell-specific
‘gene expression signals’ by pooling together the transcriptional
response to the same drug but from different experimental settings
(i.e. different cell lines, dosages or observation times). These
problems have been tackled by designing ad hoc similarity scores
[58] and genome-wide metrics [44,59,60].
RNA-seq technology might overcome many of these limitations,
because it can detect amounts of RNA over a wider dynamic range.
In the long run, RNA-seq could replace microarrays for SDE analysis;
meanwhile use of microarray data remains attractive, being not only
a simpler and more cost-effective technology but also one with a vast
collection of already publicly available data.
Concluding remarks
We have reviewed approaches using microarray data to assist in the
elucidation of compound MoA with the specific goal of identifying356 www.drugdiscoverytoday.comnew potential applications for existing drugs. A significant number
of published results show that microarray technology provides a
unique opportunity to identify repositionable drugs by exploiting
the vast amount of existing publicly available data where the
potential has not yet been fully capitalised.
The methods we described do not consider mechanistic aspects,
but simply use transcriptional signatures as readouts from the
‘black-box’ of cellular mechanisms. Therefore, they cannot pro-
vide any information about cell signalling pathways where a
deregulation can result in an observed expression signature.
It could be argued that as long as the drug works the mechanism
is a secondary consideration. But at the same time, it is reasonable
to expect that additional insight into a MoA for a given drug can
be obtained by integrating expression data with knowledge of
(and ideally data from) the systems in which the drugs operate,
known regulatory relationships between genes and signalling
pathway maps.
The challenge for the future will be to take current analyses to a
higher level, integrating signatures and mechanistic insights
inferred by other recently developed approaches. This will require
repositories of comprehensive gene expression data for disease
states and compound effects, and integration with prior knowl-
edge of cellular networks on which drugs operate, and further
development of computational methods to translate this data into
effective medicines.
So far, recent results encouragingly illustrate that computational
approaches using public gene expression microarray data can be
successfully employed to infer new potential drug therapies. We
argue that this can (and probably will) be further exploited in the
near future.
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